



Policy Statement; Prescribing of Brimonidine Tartrate 3mg/g Gel (Mirvaso®) is not supported

Mid-Essex Clinical Commissioning Group does not support the prescribing of Brimonidine tartrate 3mg/g Gel (Mirvaso®) as it is considered to be a cosmetic product.

Mirvaso® contains the active ingredient Brimonidine tartrate 3mg/g and is licensed for symptomatic treatment of facial erythema of rosacea in adult patients. It achieves this by direct vasoconstriction of superficial peripheral blood vessels.

Its use is considered to be cosmetic in nature and therefore Mirvaso® is **not** recommended for prescribing.

Refer to the [Rosacea treatment pathway](#) (LINK).

For further information please refer to the East of England Priorities Advisory Committee guidance statement January 2015.

[PAC – Brimonidine gel](#)

Providers commissioned to provide services on behalf of Mid-Essex CCG are reminded that they are required to follow the Mid-Essex CCG formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification).

See Mid-Essex CCG website – Medicines Optimisation page for all prescribing guidance:

<http://midessexccg.nhs.uk/your-health-services/medicines-optimisation>

Title	Brimonidine tartrate 3mg/g gel (Mirvaso®)
Document reference	BrimonidinePOL201502V2.0FINAL
Author	Medicines Optimisation Team, Mid Essex CCG
Reference:	PrescQIPP Priorities Advisory Committee Jan 2015
Approved by	Mid Essex Medicines Management Committee Chair: Donald McGeachy
Date approved	February 2015
Next review date	February 2020

Previous version	Key Changes
May 2014	Changes to format and updated guidance from Prescqipp